Bioventus (BVS) reported Q4 non-GAAP earnings Tuesday of $0.15 per share, up from $0.07 a year earlier.
Three analysts surveyed by FactSet expected $0.08.
Revenue for the quarter ended Dec. 31 was $153.6 million, up from $135.4 million a year earlier.
Three analysts surveyed by FactSet expected $145.2 million.
Bioventus said it expects 2025 non-GAAP EPS of $0.64 to $0.68. Three analysts surveyed by FactSet expect $0.55.
Bioventus also said it expects 2025 net sales of $560 million to $570 million. Three analysts surveyed by FactSet expect $554.6 million.
The company's shares were up more than 26% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.